OncoPharm

Latest Episodes:

PROpel and Cilostazol to Prevent Paclitaxel Neuropathy Jun 01, 2023

Show notes

Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population. Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol? PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043 Cilostazol RCT: https://doi.org/10.1002/phar.2830 Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514

Epcoritamab May 25, 2023

Show notes

We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.

Trimodality Treatment For Bladder Cancer May 18, 2023

Show notes

A recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use. Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5

GAIA-CLL13 & COSMIC-313 May 11, 2023

Show notes

Today's Pod discusses... 1) A large trial comparing 4 different CLL treatments GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093 2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851 3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809

SUNLIGHT May 04, 2023

Show notes

Talking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression." SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963

QuANTUM First (Quizartinib 1st Line in AML) Apr 27, 2023

Show notes

Quizartinib vs. Placebo(?) + Chemo in newly diagnosed AML. We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future. Link: https://doi.org/10.1016/S0140-6736(23)00464-6

ICI + Bacterial Supplementation Apr 20, 2023

Show notes

We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group. We discuss what to look for in the future studies that are likely to follow with similar methods.

Neoadjuvant Chemo In Breast Cancer Apr 13, 2023

Show notes

The Landmarks of OncoPharm series returns to discuss NSABP's B18 story of neoadjuvant vs. adjuvant AC in stages I & II breast cancer from 1998. B18: https://pubmed.ncbi.nlm.nih.gov/?term=36989610 Flashback Flashforeward: https://pubmed.ncbi.nlm.nih.gov/?term=36989608

Olanzapine & Pembrolizumab (endometrial, urothelial) Updates Apr 06, 2023

Show notes

Lots of updates: Olanzapine increases weight gain, QOL in some advanced cancer: https://pubmed.ncbi.nlm.nih.gov/?term=36977285 Chemotherapy Toxicity - When Less is More: https://www.nejm.org/doi/full/10.1056/NEJMcibr1202395 Pembro + Chemo improves PFS > chemo alone in advanced endometrial cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312 Enfortumab vedotin + pembrolizumab gets an accelerated approval for cisplatin-ineligible patients with urothelial carcinoma. Safety signals seen.

[Re-release] Tales of Brave Iressa (2017) Mar 30, 2023

Show notes

With new Pod this week, we're re-releasing the 2nd episode from way back in 2017 that provides a historical overview of how the use of EGFR TKIs changed from their use in all NSLCLC to only with activating mutations.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected